Skip to main content

Fidelity's 10 Best-Performing Mutual Funds

Gold, materials and pharmaceuticals stocks powered Fidelity Investments' mutual funds.
  • Author:
  • Publish date:

BOSTON (

TheStreet

) -- Fidelity's 10 best-performing funds in November were led by gold. Now may be an attractive time to buy bullion and mutual funds such as

Fidelity Select Gold Portfolio

(FSAGX) - Get Fidelity Select Gold Portfolio Report

after prices fell to the lowest level in more than a month.

The gold-mining fund popped 18% in a month, bringing a one-year gain to 89%. Large holdings include

Barrick Gold

(ABX)

,

Goldcorp

(GG)

,

Newmont Mining

(NEM) - Get Newmont Corporation Report

and

TheStreet Recommends

Agnico-Eagle Mines

(AEM) - Get Agnico Eagle Mines Limited Report

.

Fidelity Select Gold made the list of the

best-performing large stock mutual funds

as did

Fidelity Latin America Fund

(FLATX) - Get Fidelity Latin American Report

.

The third best-performing Fidelity fund in November was the

Fidelity Select Materials Portfolio

(FSDPX) - Get Fidelity Select Materials Report

, up 11%. Top holdings are allocated to

Dow Chemical

(DOW) - Get Dow, Inc. Report

, 9.2%;

Freeport-McMoRan Copper

(FCX) - Get Freeport-McMoRan, Inc. Report

, 7.6%;

Du Pont

(DD) - Get DuPont de Nemours, Inc. Report

, 7.0%. President Barack Obama's infrastructure spending has helped the mutual fund's holdings.

The

Fidelity Select Pharmaceutical Portfolio

(FPHAX) - Get Fidelity Select Pharmaceuticals Report

earned a rating of A-minus, or "buy," the highest in the following table. Many parts of the health-care overhaul bill working its way through the U.S. Senate are stoking controversy. What's not up for debate is that the pharmaceutical lobby has insulated their members from having to negotiate lower drug prices.

An increased number of Americas with health insurance stands to benefit fund holdings such as

Pfizer

(PFE) - Get Pfizer Inc. Report

,

Johnson & Johnson

(JNJ) - Get Johnson & Johnson Report

,

Merck

(MRK) - Get Merck & Co., Inc. Report

and

Abbott Laboratories

(ABT) - Get Abbott Laboratories Report

For the best-rated mutual funds, check out our

Top Rated Mutual Funds

page.

Kevin Baker became the senior financial analyst for TSC Ratings upon the August 2006 acquisition of Weiss Ratings by TheStreet.com, covering mutual funds. He joined the Weiss Group in 1997 as a banking and brokerage analyst. In 1999, he created the Weiss Group's first ratings to gauge the level of risk in U.S. equities. Baker received a B.S. degree in management from Rensselaer Polytechnic Institute and an M.B.A. with a finance specialization from Nova Southeastern University.